Your session is about to expire
← Back to Search
Intraocular Lens
Tecnis Eyhance for Pseudoaphakia
N/A
Waitlist Available
Research Sponsored by Johnson & Johnson Surgical Vision, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group
Summary
This trial compares two types of artificial lenses used in cataract surgery, the TECNIS Eyhance IOL and the TECNIS 1-piece IOL. The TECNIS Eyhance IOL is a new lens designed to enhance intermediate vision, while the TECNIS 1-piece IOL is a standard lens. It targets patients who need lens implants in both eyes. The lenses help restore clear vision by replacing the cloudy natural lens with a clear one.
Eligible Conditions
- Pseudoaphakia
- Cataract
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
MONOCULAR BEST-CORRECTED DISTANCE VISUAL ACUITY (BCDVA)
Secondary study objectives
MONOCULAR DISTANCE-CORRECTED INTERMEDIATE VISUAL ACUITY AT 66 CM (DCVA66)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Study LensExperimental Treatment1 Intervention
Tecnis Eyhance
Group II: Control LensActive Control1 Intervention
Tecnis 1 piece IOL (Intraocular lens)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tecnis Eyhance
2021
N/A
~230
Find a Location
Who is running the clinical trial?
Johnson & Johnson Surgical Vision, Inc.Lead Sponsor
36 Previous Clinical Trials
8,127 Total Patients Enrolled
Johnson & Johnson Surgical Vision Clinical TrialsStudy DirectorJohnson & Johnson Surgical Vision
17 Previous Clinical Trials
2,793 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger